



## **ReShape Lifesciences to Host Second Quarter 2018 Conference Call on August 14, 2018**

August 3, 2018

SAN CLEMENTE, CA / ACCESSWIRE / August 3, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the second quarter 2018 on Tuesday, August 14, 2018 at 1:30 PM Pacific Time.

Individuals interested in listening to the conference call may do so by dialing (877) 280-7473 for domestic callers or (707) 287-9370 for international callers, using Conference ID: 4849065. To listen to a live webcast or a replay, please visit the investor relations section of the Company website at [ir.reshapelifesciences.com](http://ir.reshapelifesciences.com).

### **About ReShape Lifesciences Inc.**

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m<sup>2</sup> Body Mass Index (BMI) and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is designed to help patients with a 40-45 kg/m<sup>2</sup>, or a 35-39.9 kg/m<sup>2</sup> BMI and at least one co-morbidity feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

### **Investor Contact:**

Scott Youngstrom  
Chief Financial Officer  
ReShape Lifesciences Inc.  
949-429-6680 x106  
[syoungstrom@reshapelifesci.com](mailto:syoungstrom@reshapelifesci.com)

Debbie Kaster  
Investor Relations  
Gilmartin Group  
415-937-5403  
[debbie@gilmartinir.com](mailto:debbie@gilmartinir.com)

SOURCE: ReShape Lifesciences Inc.